[go: up one dir, main page]

JP7030802B2 - ナフチリジノン誘導体および不整脈の治療におけるそれらの使用 - Google Patents

ナフチリジノン誘導体および不整脈の治療におけるそれらの使用 Download PDF

Info

Publication number
JP7030802B2
JP7030802B2 JP2019520981A JP2019520981A JP7030802B2 JP 7030802 B2 JP7030802 B2 JP 7030802B2 JP 2019520981 A JP2019520981 A JP 2019520981A JP 2019520981 A JP2019520981 A JP 2019520981A JP 7030802 B2 JP7030802 B2 JP 7030802B2
Authority
JP
Japan
Prior art keywords
chloro
dichlorophenyl
methyl
naphthylidine
naphthalidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019520981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531326A5 (zh
JP2019531326A (ja
Inventor
バーブ，ギヨーム
レイモンド ベベルニッツ，グレゴリー
ゲン，シコン
エフシミウ，ハティス ベルジン ガルゲーズ
リャオ，ルヴ
マ，フペン
モ，ルォウェィ
トーマス パーカー，デイヴィッド
ペン，ユンシャン
プカート，ステファン
健 山田
佳代 八十島
スミス，ニコラ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2019531326A publication Critical patent/JP2019531326A/ja
Publication of JP2019531326A5 publication Critical patent/JP2019531326A5/ja
Application granted granted Critical
Publication of JP7030802B2 publication Critical patent/JP7030802B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019520981A 2016-10-21 2017-10-19 ナフチリジノン誘導体および不整脈の治療におけるそれらの使用 Active JP7030802B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662410930P 2016-10-21 2016-10-21
US62/410,930 2016-10-21
CNPCT/CN2016/102928 2016-10-21
CN2016102928 2016-10-21
US201662413292P 2016-10-26 2016-10-26
US62/413,292 2016-10-26
PCT/IB2017/056515 WO2018073788A1 (en) 2016-10-21 2017-10-19 Naphthyridinone derivatives and their use in the treatment of arrhythmia

Publications (3)

Publication Number Publication Date
JP2019531326A JP2019531326A (ja) 2019-10-31
JP2019531326A5 JP2019531326A5 (zh) 2020-11-26
JP7030802B2 true JP7030802B2 (ja) 2022-03-07

Family

ID=60409317

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520981A Active JP7030802B2 (ja) 2016-10-21 2017-10-19 ナフチリジノン誘導体および不整脈の治療におけるそれらの使用

Country Status (33)

Country Link
US (3) US10266531B2 (zh)
EP (2) EP4141006A1 (zh)
JP (1) JP7030802B2 (zh)
KR (1) KR102540872B1 (zh)
CN (1) CN109843887B (zh)
AU (2) AU2017344489C1 (zh)
BR (1) BR112019007863A2 (zh)
CA (1) CA3038624A1 (zh)
CL (1) CL2019001023A1 (zh)
CO (1) CO2019003894A2 (zh)
CR (1) CR20190201A (zh)
CU (1) CU24599B1 (zh)
DO (1) DOP2019000100A (zh)
EC (1) ECSP19026973A (zh)
ES (1) ES2934234T3 (zh)
FI (1) FI3529251T3 (zh)
HR (1) HRP20221516T1 (zh)
HU (1) HUE060882T2 (zh)
IL (1) IL266128B (zh)
JO (1) JOP20190086A1 (zh)
LT (1) LT3529251T (zh)
MX (1) MX2019004484A (zh)
PE (1) PE20190735A1 (zh)
PH (1) PH12019500849A1 (zh)
PL (1) PL3529251T3 (zh)
PT (1) PT3529251T (zh)
RS (1) RS63841B1 (zh)
SA (1) SA519401614B1 (zh)
SG (1) SG11201902529WA (zh)
SI (1) SI3529251T1 (zh)
TW (1) TWI759343B (zh)
UY (1) UY37445A (zh)
WO (1) WO2018073788A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
CA3104647A1 (en) * 2018-06-27 2020-01-02 Bristol-Myers Squibb Company Naphthyridinone compounds useful as t cell activators
WO2022074567A1 (en) * 2020-10-06 2022-04-14 Novartis Ag Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia
CN115677739A (zh) * 2021-07-31 2023-02-03 华南理工大学 一种o,o-二氟化硼配合物的制备方法
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
WO2024241229A1 (en) * 2023-05-24 2024-11-28 Novartis Ag Naphthyridinone derivatives for the treatment of a disease or disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504808A (ja) 2001-09-26 2005-02-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 抗糖尿病薬としての１，６−ナフチリジン誘導体
JP2011512324A (ja) 2008-02-22 2011-04-21 大塚製薬株式会社 ベンゾジアゼピン化合物及び医薬組成物

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
IL51092A0 (en) 1976-12-10 1977-02-28 Abic Ltd Naphthyridine derivatives and their preparation
JPS57176957A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
JPS57176959A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation
JPS57176956A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
JPS57176958A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4698341A (en) 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
EP0787720B1 (en) 1994-10-20 2003-07-16 Wakunaga Seiyaku Kabushiki Kaisha Pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient
US6211375B1 (en) 1996-04-19 2001-04-03 Wakunaga Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents containing the same as the active ingredient
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
KR100516379B1 (ko) 1996-11-28 2005-09-26 와쿠나가 세이야쿠 가부시키 가이샤 신규 피리돈카르복실산 유도체 또는 그의 염 및 이를 유효 성분으로 하는 의약
AU4429799A (en) 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
EP1107759A1 (en) 1998-08-03 2001-06-20 Basf Corporation Pyridinones for the treatment of sexual dysfunction
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6521607B1 (en) 1999-09-23 2003-02-18 Pharmacia Corporation (R)-chiral halogenated substituted N-phenoxy N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
KR20020089437A (ko) 2000-04-12 2002-11-29 노파르티스 아게 유기 화합물의 배합
JP2003040866A (ja) 2001-07-31 2003-02-13 Nippon Kayaku Co Ltd Ｎ置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤
US20040248956A1 (en) 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
WO2003101988A2 (en) 2002-05-31 2003-12-11 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
DE60307483T2 (de) 2002-08-07 2007-07-05 Novartis Ag Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
DE60321593D1 (de) 2002-11-18 2008-07-24 Novartis Ag Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron
US20060194782A1 (en) 2003-09-18 2006-08-31 Altana Pharma Ag Pharmacologically active imidazo[4,5-c] pyridines
WO2005030217A1 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Quinazoline potassium channel inhibitors
EP1735320B1 (en) 2004-03-26 2009-06-17 Eli Lilly And Company Compounds and methods for treating dyslipidemia
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
US20080076794A1 (en) 2004-05-28 2008-03-27 Peter Herold Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
CA2568165A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
BRPI0511621A (pt) 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
DK2502911T3 (en) 2004-06-24 2017-06-06 Vertex Pharma Modulators of ATP-binding cassette transporters
TW200611897A (en) 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1783114A1 (en) 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
JP5460054B2 (ja) 2005-11-23 2014-04-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法
TW200804378A (en) 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
WO2007116908A1 (ja) 2006-04-04 2007-10-18 Taiyo Nippon Sanso Corporation メタン分離方法、メタン分離装置及びメタン利用システム
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
RU2009110442A (ru) 2006-08-25 2010-09-27 Новартис АГ (CH) Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой
US8143278B2 (en) 2006-12-18 2012-03-27 Novartis Ag Organic compounds
BRPI0721290A2 (pt) 2006-12-18 2014-03-25 Novartis Ag Compostos orgânicos
JP2010513482A (ja) 2006-12-18 2010-04-30 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのイミダゾール類
TW200904416A (en) 2007-03-29 2009-02-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
WO2010012745A2 (en) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
JP2013501766A (ja) 2009-08-10 2013-01-17 ユーシーエル ビジネス パブリック リミテッド カンパニー 固体基材の官能化
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
US8809541B2 (en) 2010-08-25 2014-08-19 Neopharm Co., Ltd. Heterocyclic compound, and composition for treating inflammatory diseases using same
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
RU2629111C2 (ru) 2011-07-12 2017-08-24 Ф.Хоффманн-Ля Рош Аг Аминометилхинолоны, полезные при лечении jnk-опосредованного расстройства
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP2855472B1 (en) 2012-04-05 2016-09-14 Boehringer Ingelheim International GmbH Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
US9067894B1 (en) 2013-03-07 2015-06-30 Vanderbilt University Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest
WO2014152317A2 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating gonorrhea infections using quinolone antibiotics
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AR096022A1 (es) 2013-04-11 2015-12-02 Basf Se Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales
WO2015019347A1 (en) 2013-08-08 2015-02-12 Yeda Research And Development Company Ltd. Girk as a therapeutic target of immune disorders and a marker of b cell subtypes
WO2015098693A1 (ja) 2013-12-26 2015-07-02 学校法人近畿大学 ピリドンカルボン酸系抗菌薬のアルコキシカルボニルヘミアセタール型エステルプロドラッグ
JP2017524028A (ja) 2014-08-21 2017-08-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 薬剤としてのｒｉｐ１キナーゼ阻害剤である複素環式アミド
CR20170566A (es) * 2015-06-09 2018-03-20 Bayer Pharma AG Moduladores alostéricos positivos del receptor muscarínico m2
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504808A (ja) 2001-09-26 2005-02-17 バイエル・フアーマシユーチカルズ・コーポレーシヨン 抗糖尿病薬としての１，６−ナフチリジン誘導体
JP2011512324A (ja) 2008-02-22 2011-04-21 大塚製薬株式会社 ベンゾジアゼピン化合物及び医薬組成物

Also Published As

Publication number Publication date
CR20190201A (es) 2019-06-04
SA519401614B1 (ar) 2022-06-12
PL3529251T3 (pl) 2023-01-30
US10844055B2 (en) 2020-11-24
RS63841B1 (sr) 2023-01-31
US20210284635A1 (en) 2021-09-16
AU2020204341B2 (en) 2021-07-01
KR20190066052A (ko) 2019-06-12
DOP2019000100A (es) 2019-06-16
ECSP19026973A (es) 2019-04-30
AU2017344489C1 (en) 2021-12-23
ES2934234T3 (es) 2023-02-20
LT3529251T (lt) 2023-01-10
US10266531B2 (en) 2019-04-23
CU24599B1 (es) 2022-06-06
AU2017344489B2 (en) 2020-04-02
JP2019531326A (ja) 2019-10-31
UY37445A (es) 2018-05-31
CL2019001023A1 (es) 2019-06-21
WO2018073788A1 (en) 2018-04-26
CO2019003894A2 (es) 2019-04-30
RU2019115344A3 (zh) 2021-02-20
US20190263803A1 (en) 2019-08-29
RU2019115344A (ru) 2020-11-24
US11530213B2 (en) 2022-12-20
EP3529251B1 (en) 2022-10-05
TW201819377A (zh) 2018-06-01
JOP20190086A1 (ar) 2019-04-18
IL266128A (en) 2019-06-30
CN109843887B (zh) 2022-05-10
CA3038624A1 (en) 2018-04-26
PH12019500849A1 (en) 2019-12-02
SG11201902529WA (en) 2019-05-30
HRP20221516T1 (hr) 2023-02-17
IL266128B (en) 2021-06-30
CU20190042A7 (es) 2019-11-04
CN109843887A (zh) 2019-06-04
BR112019007863A2 (pt) 2019-07-02
PE20190735A1 (es) 2019-05-23
AU2017344489A1 (en) 2019-04-11
EP4141006A1 (en) 2023-03-01
HUE060882T2 (hu) 2023-04-28
FI3529251T3 (fi) 2023-01-13
SI3529251T1 (sl) 2023-01-31
AU2020204341A1 (en) 2020-07-16
MX2019004484A (es) 2019-08-05
US20180111932A1 (en) 2018-04-26
KR102540872B1 (ko) 2023-06-08
PT3529251T (pt) 2022-12-23
TWI759343B (zh) 2022-04-01
EP3529251A1 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
JP7030802B2 (ja) ナフチリジノン誘導体および不整脈の治療におけるそれらの使用
US11639353B2 (en) Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors
JP7550870B2 (ja) Ｙａｐ／ｔａｚ－ｔｅａｄタンパク質－タンパク質相互作用阻害剤としてのビアリール誘導体
US11884661B2 (en) 3-substituted propionic acids as αV integrin inhibitors
JP6964576B2 (ja) 置換４−アザインドール及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
TW202000645A (zh) 苯基吡咯啶酮甲醯肽2受體促效劑
KR20190092560A (ko) Jak 패밀리의 키나제의 억제제로서의 이미다조피롤로피리딘
CN106536508A (zh) 用于治疗阿尔茨海默病的具有胆碱能毒蕈碱m1受体正变构调节剂活性的异吲哚啉‑1‑酮衍生物
EA024068B1 (ru) Производные бициклических гетероциклов для лечения пульмонарной артериальной гипертонии
EA020275B1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
AU2013344604A1 (en) Dihydropyrazole GPR40 modulators
EP2720546A1 (en) Trpv4 antagonists
CA3218569A1 (en) Lpa receptor antagonists and uses thereof
CN114786675A (zh) 小分子溴结构域抑制剂及其用途
RU2774273C2 (ru) Новые производные нафтиридинона и их применение в лечении аритмии
EA038455B1 (ru) Новые производные нафтиридинона и их применение в лечении аритмии
KR20240093844A (ko) Gpr39 단백질의 길항제
TW201910325A (zh) 吲哚衍生物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201014

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220222

R150 Certificate of patent or registration of utility model

Ref document number: 7030802

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250